Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

Office of the Revisor of Statutes

Key: (1) language to be deleted (2) new language

CHAPTER 240--H.F.No. 2508

An act

relating to public safety; aligning state-controlled substance schedules with federal controlled substance schedules; modifying the authority of the Board of Pharmacy to regulate controlled substances; providing for penalties;

amending Minnesota Statutes 2010, sections 152.02, as amended; 152.18, subdivision 1; Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2010, section 152.02, as amended by Laws 2011, chapter 53, sections 4 and 5, is amended to read:

152.02 SCHEDULES OF CONTROLLED SUBSTANCES; ADMINISTRATION OF CHAPTER.

Subdivision 1.

Five schedules.

There are established five schedules of controlled substances, to be known as Schedules I, II, III, IV, and V. deleted text begin Suchdeleted text end new text begin The new text end schedules deleted text begin shall initiallydeleted text end consist of the substances listed in this section by whatever official name, common or usual name, chemical name, or trade name designated.

Subd. 2.

Schedule I.

deleted text begin The following items are listed in Schedule I: deleted text end new text begin (a) Schedule I consists of the substances listed in this subdivision. new text end

deleted text begin (1)deleted text end new text begin (b) Opiates. Unless specifically excepted or unless listed in another schedule,new text end any of the following substances, including theirnew text begin analogs,new text end isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, deleted text begin unless specifically excepted,deleted text end whenever the existence of thenew text begin analogs,new text end isomers, esters, ethers and salts is possible deleted text begin within the specific chemical designationdeleted text end :

new text begin (1) new text end acetylmethadol;

new text begin (2) new text end allylprodine;

new text begin (3) new text end alphacetylmethadolnew text begin (except levo-alphacetylmethadol, also known as levomethadyl acetate)new text end ;

new text begin (4) new text end alphameprodine;

new text begin (5) new text end alphamethadol;

new text begin (6) alpha-methylfentanyl new text end benzethidine;

new text begin (7) new text end betacetylmethadol;

new text begin (8) new text end betameprodine;

new text begin (9) new text end betamethadol;

new text begin (10) new text end betaprodine;

new text begin (11) new text end clonitazene;

new text begin (12) new text end dextromoramide; deleted text begin dextrorphan;deleted text end

new text begin (13)new text end diampromide;

new text begin (14) new text end diethyliambutene;

new text begin (15) difenoxin; new text end

new text begin (16) new text end dimenoxadol;

new text begin (17) new text end dimepheptanol;

new text begin (18) new text end dimethyliambutene;

new text begin (19) new text end dioxaphetyl butyrate;

new text begin (20) new text end dipipanone;

new text begin (21) new text end ethylmethylthiambutene;

new text begin (22) new text end etonitazene;

new text begin (23) new text end etoxeridine;

new text begin (24) new text end furethidine;

new text begin (25) new text end hydroxypethidine;

new text begin (26) new text end ketobemidone;

new text begin (27) new text end levomoramide;

new text begin (28) new text end levophenacylmorphan;

new text begin (29) 3-methylfentanyl; new text end

new text begin (30) acetyl-alpha-methylfentanyl; new text end

new text begin (31) alpha-methylthiofentanyl; new text end

new text begin (32) benzylfentanyl beta-hydroxyfentanyl; new text end

new text begin (33) beta-hydroxy-3-methylfentanyl; new text end

new text begin (34) 3-methylthiofentanyl; new text end

new text begin (35) thenylfentanyl; new text end

new text begin (36) thiofentanyl; new text end

new text begin (37) para-fluorofentanyl; new text end

new text begin (38) new text end morpheridine;

new text begin (39) 1-methyl-4-phenyl-4-propionoxypiperidine; new text end

new text begin (40) new text end noracymethadol;

new text begin (41) new text end norlevorphanol;

new text begin (42) new text end normethadone;

new text begin (43) new text end norpipanone;

new text begin (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP); new text end

new text begin (45) new text end phenadoxone;

new text begin (46) new text end phenampromide;

new text begin (47) new text end phenomorphan;

new text begin (48) new text end phenoperidine;

new text begin (49) new text end piritramide;

new text begin (50) new text end proheptazine;

new text begin (51) new text end properidine;

new text begin (52) propiram; new text end

new text begin (53) new text end racemoramide;

new text begin (54) tilidine; new text end

new text begin (55) new text end trimeperidine.

deleted text begin (2)deleted text end new text begin (c) Opium derivatives.new text end Any of the following deleted text begin opium derivativesdeleted text end new text begin substancesnew text end , theirnew text begin analogs,new text end salts, isomersnew text begin ,new text end and salts of isomers, unless specifically exceptednew text begin or unless listed in another schedulenew text end , whenever the existence of thenew text begin analogs,new text end salts, isomers and salts of isomers is possible deleted text begin within the specific chemical designationdeleted text end :

new text begin (1) new text end acetorphine;

new text begin (2) new text end acetyldihydrocodeine; deleted text begin acetylcodone;deleted text end

new text begin (3) new text end benzylmorphine;

new text begin (4) new text end codeine methylbromide;

new text begin (5) new text end codeine-n-oxide;

new text begin (6) new text end cyprenorphine;

new text begin (7) new text end desomorphine;

new text begin (8) new text end dihydromorphine;

new text begin (9) new text end new text begin drotebanol; new text end

new text begin (10) new text end etorphine;

new text begin (11) new text end heroin;

new text begin (12) new text end hydromorphinol;

new text begin (13) new text end methyldesorphine; deleted text begin methylhydromorphinedeleted text end

new text begin (14) methyldihydromorphinenew text end ;

new text begin (15) new text end morphine methylbromide;

new text begin (16) new text end morphine methylsulfonate;

new text begin (17) new text end morphine-n-oxide;

new text begin (18) new text end myrophine;

new text begin (19) new text end nicocodeine;

new text begin (20) new text end nicomorphine;

new text begin (21) new text end normorphine;

new text begin (22) new text end pholcodine;

new text begin (23) new text end thebacon.

deleted text begin (3)deleted text end new text begin (d)new text end new text begin Hallucinogens.new text end Any material, compound, mixture or preparation which contains any quantity of the following deleted text begin hallucinogenicdeleted text end substances, theirnew text begin analogs,new text end salts, isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of thenew text begin analogs,new text end salts, isomers, and salts of isomers is possible:

deleted text begin 3,4-methylenedioxy amphetaminedeleted text end new text begin (1) methylenedioxy amphetaminenew text end ;

deleted text begin 3,4-methylenedioxymethamphetaminedeleted text end new text begin (2) methylenedioxymethamphetaminenew text end ;

new text begin (3) methylenedioxy-N-ethylamphetamine (MDEA); new text end

new text begin (4) n-hydroxy-methylenedioxyamphetamine; new text end

new text begin (5) new text end 4-bromo-2,5-dimethoxyamphetaminenew text begin (DOB)new text end ;

new text begin (6) new text end 2,5-dimethoxyamphetaminenew text begin (2,5-DMA)new text end ;

new text begin (7) new text end 4-methoxyamphetamine;

new text begin (8) new text end 5-methoxy-3, 4-methylenedioxy amphetamine;

new text begin (9) alpha-ethyltryptamine; new text end

new text begin (10) new text end bufotenine;

new text begin (11) new text end diethyltryptamine;

new text begin (12) new text end dimethyltryptamine;

new text begin (13) new text end 3,4,5-trimethoxy amphetamine;

new text begin (14) new text end 4-methyl-2, 5-dimethoxyamphetaminenew text begin (DOM)new text end ;

new text begin (15) new text end ibogaine;

new text begin (16) new text end lysergic acid diethylamidenew text begin (LSD)new text end ; deleted text begin marijuana;deleted text end

new text begin (17) new text end mescaline;

new text begin (18) parahexyl; new text end

new text begin (19) new text end N-ethyl-3-piperidyl benzilate;

new text begin (20) new text end N-methyl-3-piperidyl benzilate;

new text begin (21) new text end psilocybin;

new text begin (22) new text end psilocyn;

deleted text begin Tetrahydrocannabinols; 1-(1-(2-thienyl) cyclohexyl) piperidinedeleted text end new text begin (23) tenocyclidine (TPCP or TCP)new text end ;

new text begin (24) new text end N-ethyl-1-phenyl-cyclohexylaminenew text begin (PCE)new text end ;

new text begin (25) new text end 1-(1-phenylcyclohexyl) pyrrolidinenew text begin (PCPy);new text end

new text begin (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy); new text end

new text begin (27) 4-chloro-2,5-dimethoxyamphetamine (DOC); new text end

new text begin (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET); new text end

new text begin (29) 4-iodo-2,5-dimethoxyamphetamine (DOI); new text end

new text begin (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B); new text end

new text begin (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C); new text end

new text begin (32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD)new text end ;

deleted text begin 2,5-dimethoxy-4-ethylphenethylamine, also known asdeleted text end new text begin (33) 4-ethyl-2,5-dimethoxyphenethylamine (new text end 2C-Enew text begin )new text end ;

deleted text begin 2,5-dimethoxy-4-iodophenethylamine, also known asdeleted text end new text begin (34) 4-iodo-2,5-dimethoxyphenethylamine (new text end 2C-Inew text begin );new text end

new text begin (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P); new text end

new text begin (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4); new text end

new text begin (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7); new text end

new text begin (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2-CB-FLY); new text end

new text begin (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY); new text end

new text begin (40) alpha-methyltryptamine (AMT); new text end

new text begin (41) N,N-diisopropyltryptamine (DiPT); new text end

new text begin (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT); new text end

new text begin (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET); new text end

new text begin (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT); new text end

new text begin (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT); new text end

new text begin (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT); new text end

new text begin (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); new text end

new text begin (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT); new text end

new text begin (49) 5-methoxy-α-methyltryptamine (5-MeO-AMT); new text end

new text begin (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); new text end

new text begin (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT); new text end

new text begin (52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT); new text end

new text begin (53) 5-methoxy-α-ethyltryptamine (5-MeO-AET); new text end

new text begin (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT); new text end

new text begin (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET); new text end

new text begin (56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT); new text end

new text begin (57) methoxetamine (MXE); new text end

new text begin (58) 5-iodo-2-aminoindane (5-IAI); new text end

new text begin (59) 5,6-methylenedioxy-2-aminoindane (MDAI)new text end .

deleted text begin (4)deleted text end new text begin (e)new text end Peyotedeleted text begin , providingdeleted text end new text begin .new text end new text begin All parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, its seeds or extracts.new text end The listing of peyote as a controlled substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian Church, and members of the American Indian Church are exempt from registration. Any person who manufactures peyote for or distributes peyote to the American Indian Church, however, is required to obtain federal registration annually and to comply with all other requirements of law.

deleted text begin (5)deleted text end new text begin (f) Central nervous system depressants.new text end Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances deleted text begin having a depressant effect on the central nervous system, including itsdeleted text end new text begin , their analogs,new text end salts, isomers, and salts of isomers whenever the existence of thenew text begin analogs,new text end salts, isomers, and salts of isomers is possible deleted text begin within the specific chemical designationdeleted text end :

new text begin (1) new text end mecloqualone;

new text begin (2) methaqualone; new text end

new text begin (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers; new text end

new text begin (4) new text end flunitrazepam.

deleted text begin (6)deleted text end new text begin (g) Stimulants.new text end Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances deleted text begin having a stimulant effect on the central nervous system, including itsdeleted text end new text begin , their analogs,new text end salts, isomers, and salts of isomers whenever the existence of thenew text begin analogs,new text end salts, isomers, and salts of isomers is possible deleted text begin within the specific chemical designationdeleted text end :

new text begin (1) aminorex; new text end

new text begin (2) new text end cathinone;

new text begin (3) fenethylline; new text end

new text begin (4) new text end methcathinone;

new text begin (5) methylaminorex; new text end

new text begin (6) N,N-dimethylamphetamine; new text end

new text begin (7) N-benzylpiperazine (BZP); new text end

deleted text begin 4-methylmethcathinonedeleted text end new text begin (8) methylmethcathinonenew text end (mephedrone);

new text begin (9) new text end 3,4-methylenedioxy-N-methylcathinone (methylone);

deleted text begin 4-methoxymethcathinonedeleted text end new text begin (10) methoxymethcathinonenew text end (methedrone);

deleted text begin 3,4 - methylenedioxypyrovaleronedeleted text end new text begin (11) methylenedioxypyrovalerone new text end (MDPV)new text begin ;new text end

new text begin (12) fluoromethcathinone; new text end

new text begin (13) methylethcathinone (MEC); new text end

new text begin (14) 1-benzofuran-6-ylpropan-2-amine (6-APB); new text end

new text begin (15) dimethylmethcathinone (DMMC); new text end

new text begin (16) fluoroamphetamine; new text end

new text begin (17) fluoromethamphetamine; new text end

new text begin (18) α-methylaminobutyrophenone (MABP or buphedrone); new text end

new text begin (19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone); new text end

new text begin (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378); new text end

new text begin (21) naphthylpyrovalerone (naphyrone); new text end

new text begin (22) and any other substance, except bupropion or compounds listed under a different schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways: new text end

new text begin (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents; new text end

new text begin (ii) by substitution at the 3-position with an acyclic alkyl substituent; new text end

new text begin (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups; or new text end

new text begin (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structurenew text end .

deleted text begin (7)deleted text end new text begin (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids.new text end Unless specifically excepted or unless listed in another schedule, any natural or synthetic material, compound, mixture, or preparation that contains any quantity of deleted text begin a substance that is a cannabinoid receptor agonist, including, but not limited to,deleted text end the following substances deleted text begin anddeleted text end new text begin ,new text end their analogs, deleted text begin includingdeleted text end isomers, deleted text begin whether optical, positional, or geometric;deleted text end estersdeleted text begin ;deleted text end new text begin ,new text end ethersdeleted text begin ;deleted text end new text begin ,new text end saltsdeleted text begin ;deleted text end new text begin ,new text end and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible deleted text begin within the specific chemical designationdeleted text end :

deleted text begin 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015), 1-Pentyl-3-(1-naphthoyl)indole (JWH-018), 1-hexyl-3-(naphthalen-1-oyl)indole (JWH-019), 1-Butyl-3-(1-naphthoyl)indole (JWH-073), 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-081), 4-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone (JWH-098), (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone (JWH-200), 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-164), 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-203), 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210), 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250), 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), (6aR,10aR)- 9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol (HU-210), (R)-(+)-[2,3-Dihydro-5-methyl-3- (4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone (WIN-55,212-2), 2-[3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol (CP47,497), dimethylheptylpyran. deleted text end

new text begin (1) marijuana; new text end

new text begin (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of the plant, or synthetic substances with similar chemical structure and pharmacological activity to those substances contained in the plant or resinous extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol; new text end

new text begin (3) synthetic cannabinoids, including the following substances: new text end

new text begin (i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylindoles include, but are not limited to: new text end

new text begin (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678); new text end

new text begin (B) 1-Butul-3-(1-naphthoyl)indole (JWH-073); new text end

new text begin (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081); new text end

new text begin (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); new text end

new text begin (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015); new text end

new text begin (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019); new text end

new text begin (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); new text end

new text begin (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210); new text end

new text begin (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398); new text end

new text begin (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201). new text end

new text begin (ii) Napthylmethylindoles, which are any compounds containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthylmethylindoles include, but are not limited to: new text end

new text begin (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175); new text end

new text begin (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184). new text end

new text begin (iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to, (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307). new text end

new text begin (iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthylemethylindenes include, but are not limited to, E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176). new text end

new text begin (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of phenylacetylindoles include, but are not limited to: new text end

new text begin (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8); new text end

new text begin (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); new text end

new text begin (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251); new text end

new text begin (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203). new text end

new text begin (vi) Cyclohexylphenols, which are compounds containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not limited to: new text end

new text begin (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497); new text end

new text begin (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Cannabicyclohexanol or CP 47,497 C8 homologue); new text end

new text begin (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] -phenol (CP 55,940). new text end

new text begin (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of benzoylindoles include, but are not limited to: new text end

new text begin (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4); new text end

new text begin (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694); new text end

new text begin (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN 48,098 or Pravadoline). new text end

new text begin (viii) Others specifically named: new text end

new text begin (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210); new text end

new text begin (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211); new text end

new text begin (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2). new text end

deleted text begin (8)deleted text end new text begin (i)new text end A controlled substance analog, to the extent that it is implicitly or explicitly intended for human consumption.

Subd. 3.

Schedule II.

deleted text begin The following items are listed indeleted text end new text begin (a)new text end Schedule IIdeleted text begin :deleted text end new text begin consists of the substances listed in this subdivision.new text end

deleted text begin (1)deleted text end new text begin (b)new text end Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

deleted text begin (a)deleted text end new text begin (1)new text end Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiatedeleted text begin , including the following: raw opium, opium extracts, opium fluid extracts, powdered opium, granulated opium, tincture of opium, apomorphine, codeine, ethylmorphine, hydrocodone, hydromorphone, metopon, morphine, oxycodone, oxymorphone, thebainedeleted text end .

new text begin (i) Excluding: new text end

new text begin (A) apomorphine; new text end

new text begin (B) thebaine-derived butorphanol; new text end

new text begin (C) dextrophan; new text end

new text begin (D) nalbuphine; new text end

new text begin (E) nalmefene; new text end

new text begin (F) naloxone; new text end

new text begin (G) naltrexone; new text end

new text begin (H) and their respective salts; new text end

new text begin (ii) but including the following: new text end

new text begin (A) opium, in all forms and extracts; new text end

new text begin (B) codeine; new text end

new text begin (C) dihydroetorphine; new text end

new text begin (D) ethylmorphine; new text end

new text begin (E) etorphine hydrochloride; new text end

new text begin (F) hydrocodone; new text end

new text begin (G) hydromorphone; new text end

new text begin (H) metopon; new text end

new text begin (I) morphine; new text end

new text begin (J) oxycodone; new text end

new text begin (K) oxymorphone; new text end

new text begin (L) thebaine; new text end

new text begin (M) oripavine; new text end

deleted text begin (b)deleted text end new text begin (2)new text end any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause deleted text begin (a)deleted text end new text begin (1)new text end , except that these substances shall not include the isoquinoline alkaloids of opiumdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (c)deleted text end new text begin (3)new text end opium poppy and poppy strawdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (d)deleted text end new text begin (4)new text end coca leaves and any salt,new text begin cocainenew text end compound, derivative, or preparation of coca leaves, deleted text begin including cocaine and ecgonine, the salts and isomers of cocaine and ecgonine, and the salts of their isomers.deleted text end new text begin (including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine;new text end

deleted text begin (e) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (d), except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine. deleted text end new text begin (5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy). new text end

deleted text begin (2)deleted text end new text begin (c)new text end Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation:

new text begin (1) new text end alfentanil;

new text begin (2) new text end alphaprodine;

new text begin (3) new text end anileridine;

new text begin (4) new text end bezitramide;

new text begin (5) bulk dextropropoxyphene (nondosage forms); new text end

new text begin (6) carfentanil; new text end

new text begin (7) new text end dihydrocodeine;

new text begin (8) new text end dihydromorphinone;

new text begin (9) new text end diphenoxylate;

new text begin (10) new text end fentanyl;

new text begin (11) new text end isomethadone;

new text begin (12) levo-alpha-acetylmethadol (LAAM)new text end levomethorphan;

new text begin (13) new text end levorphanol;

new text begin (14) new text end metazocine;

new text begin (15) new text end methadone;

new text begin (16) new text end methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

new text begin (17) new text end moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid;

new text begin (18) new text end pethidine;

new text begin (19) new text end pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;

new text begin (20) new text end pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;

new text begin (21) new text end pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

new text begin (22) new text end phenazocine;

new text begin (23) new text end piminodine;

new text begin (24) new text end racemethorphan;

new text begin (25) new text end racemorphannew text begin ;new text end

new text begin (26) remifentanil; new text end

new text begin (27) sufentanil; new text end

new text begin (28) tapentadolnew text end .

deleted text begin (3)deleted text end new text begin (d)new text end Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

deleted text begin (a)deleted text end new text begin (1)new text end amphetamine, its salts, optical isomers, and salts of its optical isomers;

deleted text begin (b)deleted text end new text begin (2)new text end methamphetamine, its salts, isomers, and salts of its isomers;

deleted text begin (c)deleted text end new text begin (3)new text end phenmetrazine and its salts;

deleted text begin (d)deleted text end new text begin (4)new text end methylphenidatenew text begin ;new text end

new text begin (5) lisdexamfetaminenew text end .

deleted text begin (4)deleted text end new text begin (e)new text end Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

deleted text begin (a) methaqualone deleted text end

deleted text begin (b)deleted text end new text begin (1)new text end amobarbitalnew text begin ;new text end

new text begin (2) glutethimide; new text end

deleted text begin (c)deleted text end new text begin (3)new text end secobarbitalnew text begin ;new text end

deleted text begin (d)deleted text end new text begin (4)new text end pentobarbitalnew text begin ;new text end

deleted text begin (e)deleted text end new text begin (5)new text end phencyclidinenew text begin ;new text end

deleted text begin (f)deleted text end new text begin (6)new text end phencyclidine immediate precursors:

(i) 1-phenylcyclohexylaminenew text begin ;new text end

(ii) 1-piperidinocyclohexanecarbonitrilenew text begin ;new text end

new text begin (7) phenylacetonenew text end .

new text begin (f) Hallucinogenic substances: nabilone. new text end

Subd. 4.

Schedule III.

deleted text begin The following items are listed indeleted text end new text begin (a)new text end Schedule IIIdeleted text begin :deleted text end new text begin consists of the substances listed in this subdivision.new text end

deleted text begin (1) Any material, compound, mixture, or preparation which contains any quantity of Amphetamine, its salts, optical isomers, and salts of its optical isomers; Phenmetrazine and its salts; Methamphetamine, its salts, isomers, and salts of isomers; Methylphenidate; and which is required by federal law to be labeled with the symbol prescribed by 21 Code of Federal Regulations Section 1302.03 and in effect on February 1, 1976 designating that the drug is listed as a Schedule III controlled substance under federal law. deleted text end new text begin (b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: new text end

new text begin (1) benzphetamine; new text end

new text begin (2) chlorphentermine; new text end

new text begin (3) clortermine; new text end

new text begin (4) phendimetrazine. new text end

deleted text begin (2)deleted text end new text begin (c) Depressants. Unless specifically excepted or unless listed in another schedule,new text end any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

deleted text begin (a)deleted text end new text begin (1)new text end any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any scheduledeleted text begin .deleted text end new text begin ;new text end

deleted text begin (b)deleted text end new text begin (2)new text end any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the food and drug administration for marketing only as a suppositorydeleted text begin .deleted text end new text begin ;new text end

deleted text begin (c)deleted text end new text begin (3)new text end any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedulesdeleted text begin : Chlorhexadol; Glutethimide; Lysergic acid; Lysergic acid amide; Methyprylon; Sulfondiethylmethane; Sulfonethylmethane; Sulfonmethane.deleted text end new text begin ;new text end

deleted text begin (d) Gamma hydroxybutyrate, any salt, compound, derivative, or preparation of gamma hydroxybutyrate, including any isomers, esters, and ethers and salts of isomers, esters, and ethers of gamma hydroxybutyrate whenever the existence of such isomers, esters, and salts is possible within the specific chemical designation. deleted text end new text begin (4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal Food, Drug, and Cosmetic Act; new text end

new text begin (5) any of the following substances: new text end

new text begin (i) chlorhexadol; new text end

new text begin (ii) ketamine, its salts, isomers and salts of isomers; new text end

new text begin (iii) lysergic acid; new text end

new text begin (iv) lysergic acid amide; new text end

new text begin (v) methyprylon; new text end

new text begin (vi) sulfondiethylmethane; new text end

new text begin (vii) sulfonenthylmethane; new text end

new text begin (viii) sulfonmethane; new text end

new text begin (ix) tiletamine and zolazepam and any salt thereof; new text end

new text begin (x) embutramide. new text end

deleted text begin (3) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system: deleted text end

deleted text begin (a) Benzphetamine deleted text end

deleted text begin (b) Chlorphentermine deleted text end

deleted text begin (c) Clortermine deleted text end

deleted text begin (d) Mazindol deleted text end

deleted text begin (e) Phendimetrazine. deleted text end

deleted text begin (4)deleted text end new text begin (d)new text end Nalorphine.

deleted text begin (5) Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereofdeleted text end new text begin (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as followsnew text end :

deleted text begin (a)deleted text end new text begin (1) new text end not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opiumdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (b)deleted text end new text begin (2) new text end not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amountsdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (c)deleted text end new text begin (3) new text end not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opiumdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (d)deleted text end new text begin (4) new text end not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amountsdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (e)deleted text end new text begin (5) new text end not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amountsdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (f)deleted text end new text begin (6) new text end not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amountsdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (g)deleted text end new text begin (7) new text end not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amountsdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (h)deleted text end new text begin (8) new text end not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amountsdeleted text begin .deleted text end new text begin ;new text end

deleted text begin (6)deleted text end new text begin (f) new text end Anabolic steroidsdeleted text begin , whichdeleted text end new text begin and human growth hormone.new text end

new text begin (1) Anabolic steroidsnew text end , for purposes of this subdivision, means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes: deleted text begin androstanediol; androstanedione; androstenediol; androstenedione; bolasterone; boldenone; calusterone; chlorotestosterone; chorionic gonadotropin; clostebol; dehydrochloromethyltestosterone; (triangle)1-dihydrotestosterone; 4-dihydrotestosterone; drostanolone; ethylestrenol; fluoxymesterone; formebolone; furazabol; human growth hormones; 13b-ethyl-17a-hydroxygon-4-en-3-one; 4-hydroxytestosterone; 4-hydroxy-19-nortestosterone; mestanolone; mesterolone; methandienone; methandranone; methandriol; methandrostenolone; methenolone; 17a-methyl-3b, 17b-dihydroxy-5a-androstane; 17a-methyl-3a, 17b-dihydroxy-5a-androstane; 17a-methyl-3b, 17b-dihydroxyandrost-4-ene; 17a-methyl-4-hydroxynandrolone; methyldienolone; methyltrienolone; methyltestosterone; mibolerone; 17a-methyl-(triangle)1-dihydrotestosterone; nandrolone; nandrolone phenpropionate; norandrostenediol; norandrostenedione; norbolethone; norclostebol; norethandrolone; normethandrolone; oxandrolone; oxymesterone; oxymetholone; stanolone; stanozolol; stenbolone; testolactone; testosterone; testosterone propionate; tetrahydrogestrinone; trenbolone; and any salt, ester, or ether of a drug or substance described in this paragraph.deleted text end

new text begin (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane; new text end

new text begin (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; new text end

new text begin (iii) androstanedione (5[alpha]-androstan-3,17-dione); new text end

new text begin (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene; new text end

new text begin (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene); new text end

new text begin (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene); new text end

new text begin (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene); new text end

new text begin (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione); new text end

new text begin (ix) 4-androstenedione (androst-4-en-3,17-dione); new text end

new text begin (x) 5-androstenedione (androst-5-en-3,17-dione); new text end

new text begin (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); new text end

new text begin (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one); new text end

new text begin (xiii) boldione (androsta-1,4-diene-3,17-dione); new text end

new text begin (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); new text end

new text begin (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one); new text end

new text begin (xvi) dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one); new text end

new text begin (xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol); new text end

new text begin (xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); new text end

new text begin (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one); new text end

new text begin (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one); new text end

new text begin (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene); new text end

new text begin (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one); new text end

new text begin (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one); new text end

new text begin (xxiv) furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta] -hydroxygon-4-en-3-one; new text end

new text begin (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one); new text end

new text begin (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one); new text end

new text begin (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); new text end

new text begin (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); new text end

new text begin (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one); new text end

new text begin (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene); new text end

new text begin (xxxi) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); new text end

new text begin (xxxii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane; new text end

new text begin (xxxiii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; new text end

new text begin (xxxiv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene; new text end

new text begin (xxxv) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one); new text end

new text begin (xxxvi) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one); new text end

new text begin (xxxvii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one); new text end

new text begin (xxxviii) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one); new text end

new text begin (xxxix) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one); new text end

new text begin (xl) 17[alpha]-methyl-[delta]1-dihydrotestosterone (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one); new text end

new text begin (xli) nandrolone (17[beta]-hydroxyestr-4-en-3-one); new text end

new text begin (xlii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene; new text end

new text begin (xliii) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene; new text end

new text begin (xliv) 3[alpha],17[beta]-dihydroxyestr-5-ene); new text end

new text begin (xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); new text end

new text begin (xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-dione); new text end

new text begin (xlvii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one); new text end

new text begin (xlviii) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); new text end

new text begin (xlix) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one); new text end

new text begin (l) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); new text end

new text begin (li) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one); new text end

new text begin (lii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one); new text end

new text begin (liii) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one); new text end

new text begin (liv) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole); new text end

new text begin (lv) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one); new text end

new text begin (lvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone); new text end

new text begin (lvii) testosterone (17[beta]-hydroxyandrost-4-en-3-one); new text end

new text begin (lviii) tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one); new text end

new text begin (lix) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one); new text end

new text begin (lx) any salt, ester, or ether of a drug or substance described in this paragraph. new text end

Anabolic steroids are not included if they are: deleted text begin (i)deleted text end new text begin (A)new text end expressly intended for administration through implants to cattle or other nonhuman species; and deleted text begin (ii)deleted text end new text begin (B)new text end approved by the United States Food and Drug Administration for that usedeleted text begin .deleted text end new text begin ;new text end

new text begin (2) Human growth hormones. new text end

new text begin (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved product. new text end

new text begin (h) Any material, compound, mixture, or preparation containing the following narcotic drug or its salt: buprenorphine. new text end

Subd. 5.

Schedule IV.

deleted text begin The following items are listed in Schedule IV: Barbital; Butorphanol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clonazepam; Clorazepate; Diazepam; Diethylpropion; Ethchlorvynol; Ethinamate; Fenfluramine; Flurazepam; Mebutamate; Methohexital; Meprobamate except when in combination with the following drugs in the following or lower concentrations: conjugated estrogens, 0.4 mg; tridihexethyl chloride, 25mg; pentaerythritol tetranitrate, 20 mg; Methylphenobarbital; Oxazepam; Paraldehyde; Pemoline; Petrichloral; Phenobarbital; and Phenterminedeleted text end new text begin (a) Schedule IV consists of the substances listed in this subdivisionnew text end .

new text begin (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows: new text end

new text begin (1) not more than one milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; new text end

new text begin (2) dextropropoxyphene (Darvon and Darvocet). new text end

new text begin (c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible: new text end

new text begin (1) alprazolam; new text end

new text begin (2) barbital; new text end

new text begin (3) bromazepam; new text end

new text begin (4) camazepam; new text end

new text begin (5) carisoprodol; new text end

new text begin (6) chloral betaine; new text end

new text begin (7) chloral hydrate; new text end

new text begin (8) chlordiazepoxide; new text end

new text begin (9) clobazam; new text end

new text begin (10) clonazepam; new text end

new text begin (11) clorazepate; new text end

new text begin (12) clotiazepam; new text end

new text begin (13) cloxazolam; new text end

new text begin (14) delorazepam; new text end

new text begin (15) diazepam; new text end

new text begin (16) dichloralphenazone; new text end

new text begin (17) estazolam; new text end

new text begin (18) ethchlorvynol; new text end

new text begin (19) ethinamate; new text end

new text begin (20) ethyl loflazepate; new text end

new text begin (21) fludiazepam; new text end

new text begin (22) flurazepam; new text end

new text begin (23) halazepam; new text end

new text begin (24) haloxazolam; new text end

new text begin (25) ketazolam; new text end

new text begin (26) loprazolam; new text end

new text begin (27) lorazepam; new text end

new text begin (28) lormetazepam mebutamate; new text end

new text begin (29) medazepam; new text end

new text begin (30) meprobamate; new text end

new text begin (31) methohexital; new text end

new text begin (32) methylphenobarbital; new text end

new text begin (33) midazolam; new text end

new text begin (34) nimetazepam; new text end

new text begin (35) nitrazepamnordiazepam; new text end

new text begin (36) oxazepam; new text end

new text begin (37) oxazolam; new text end

new text begin (38) paraldehydepetrichloral; new text end

new text begin (39) phenobarbital; new text end

new text begin (40) pinazepam; new text end

new text begin (41) prazepam; new text end

new text begin (42) quazepam; new text end

new text begin (43) temazepam; new text end

new text begin (44) tetrazepam; new text end

new text begin (45) triazolam; new text end

new text begin (46) zaleplon; new text end

new text begin (47) zolpidem; new text end

new text begin (48) zopiclone. new text end

new text begin (d) Any material, compound, mixture, or preparation which contains any quantity of the following substance including its salts, isomers, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: fenfluramine. new text end

new text begin (e) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: new text end

new text begin (1) cathine (norpseudoephedrine); new text end

new text begin (2) diethylpropion; new text end

new text begin (3) fencamfamine; new text end

new text begin (4) fenproporex; new text end

new text begin (5) mazindol; new text end

new text begin (6) mefenorex; new text end

new text begin (7) modafinil; new text end

new text begin (8) pemoline (including organometallic complexes and chelates thereof); new text end

new text begin (9) phentermine; new text end

new text begin (10) pipradol; new text end

new text begin (11) sibutramine; new text end

new text begin (12) SPA (1-dimethylamino-1,2-diphenylethane). new text end

Subd. 6.

Schedule V; restrictions on methamphetamine precursor drugs.

(a) As used in this subdivision, the following terms have the meanings given:

(1) "methamphetamine precursor drug" means any compound, mixture, or preparation intended for human consumption containing ephedrine or pseudoephedrine as its sole active ingredient or as one of its active ingredients; and

(2) "over-the-counter sale" means a retail sale of a drug or product but does not include the sale of a drug or product pursuant to the terms of a valid prescription.

(b) The following items are listed in Schedule V:

(1) any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit; deleted text begin ordeleted text end

(iv) not more than deleted text begin 15 milligrams of anhydrous morphine per 100 milliliters or per 100 grams; anddeleted text end new text begin 100 milligrams of opium per 100 milliliters or per 100 grams; ornew text end

new text begin (v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. new text end

new text begin (2) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: pyrovalerone. new text end

new text begin (3) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers: new text end

new text begin (i) pregabalin; new text end

new text begin (ii) lacosamide. new text end

deleted text begin (2)deleted text end new text begin (4)new text end Any compound, mixture, or preparation containing ephedrine or pseudoephedrine as its sole active ingredient or as one of its active ingredients.

(c) No person may sell in a single over-the-counter sale more than two packages of a methamphetamine precursor drug or a combination of methamphetamine precursor drugs or any combination of packages exceeding a total weight of six grams, calculated as the base.

(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:

(1) packages containing not more than a total of three grams of one or more methamphetamine precursor drugs, calculated in terms of ephedrine base or pseudoephedrine base; or

(2) for nonliquid products, sales in blister packs, where each blister contains not more than two dosage units, or, if the use of blister packs is not technically feasible, sales in unit dose packets or pouches.

(e) A business establishment that offers for sale methamphetamine precursor drugs in an over-the-counter sale shall ensure that all packages of the drugs are displayed behind a checkout counter where the public is not permitted and are offered for sale only by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The establishment shall ensure that the person making the sale requires the buyer:

(1) to provide photographic identification showing the buyer's date of birth; and

(2) to sign a written or electronic document detailing the date of the sale, the name of the buyer, and the amount of the drug sold.

A document described under clause (2) must be retained by the establishment for at least three years and must at all reasonable times be open to the inspection of any law enforcement agency.

Nothing in this paragraph requires the buyer to obtain a prescription for the drug's purchase.

(f) No person may acquire through over-the-counter sales more than six grams of methamphetamine precursor drugs, calculated as the base, within a 30-day period.

(g) No person may sell in an over-the-counter sale a methamphetamine precursor drug to a person under the age of 18 years. It is an affirmative defense to a charge under this paragraph if the defendant proves by a preponderance of the evidence that the defendant reasonably and in good faith relied on proof of age as described in section 340A.503, subdivision 6.

(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to payment of a fine of not more than $1,000, or both.

(i) An owner, operator, supervisor, or manager of a business establishment that offers for sale methamphetamine precursor drugs whose employee or agent is convicted of or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal penalties for violating any of those paragraphs if the person:

(1) did not have prior knowledge of, participate in, or direct the employee or agent to commit the violation; and

(2) documents that an employee training program was in place to provide the employee or agent with information on the state and federal laws and regulations regarding methamphetamine precursor drugs.

(j) Any person employed by a business establishment that offers for sale methamphetamine precursor drugs who sells such a drug to any person in a suspicious transaction shall report the transaction to the owner, supervisor, or manager of the establishment. The owner, supervisor, or manager may report the transaction to local law enforcement. A person who reports information under this subdivision in good faith is immune from civil liability relating to the report.

(k) Paragraphs (b) to (j) do not apply to:

(1) pediatric products labeled pursuant to federal regulation primarily intended for administration to children under 12 years of age according to label instructions;

(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as being manufactured in a manner that prevents the drug from being used to manufacture methamphetamine;

(3) methamphetamine precursor drugs in gel capsule or liquid form; or

(4) compounds, mixtures, or preparations in powder form where pseudoephedrine constitutes less than one percent of its total weight and is not its sole active ingredient.

(l) The Board of Pharmacy, in consultation with the Department of Public Safety, shall certify methamphetamine precursor drugs that meet the requirements of paragraph (k), clause (2), and publish an annual listing of these drugs.

(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy pursuant to sections 151.42 to 151.51 and registered with and regulated by the United States Drug Enforcement Administration are exempt from the methamphetamine precursor drug storage requirements of this section.

(n) This section preempts all local ordinances or regulations governing the sale by a business establishment of over-the-counter products containing ephedrine or pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.

Subd. 7.

Board of Pharmacy; regulation of substances.

The Board of Pharmacy is authorized to regulate and define additional substances which contain quantities of a substance possessing abuse potential in accordance with the following criteria:

(1) The Board of Pharmacy shall place a substance in Schedule I if it finds that the substance has: A high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision.

(2) The Board of Pharmacy shall place a substance in Schedule II if it finds that the substance has: A high potential for abuse, currently accepted medical use in the United States, or currently accepted medical use with severe restrictions, and that abuse may lead to severe psychological or physical dependence.

(3) The Board of Pharmacy shall place a substance in Schedule III if it finds that the substance has: A potential for abuse less than the substances listed in Schedules I and II, currently accepted medical use in treatment in the United States, and that abuse may lead to moderate or low physical dependence or high psychological dependence.

(4) The Board of Pharmacy shall place a substance in Schedule IV if it finds that the substance has: A low potential for abuse relative to the substances in Schedule III, currently accepted medical use in treatment in the United States, and that abuse may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III.

(5) The Board of Pharmacy shall place a substance in Schedule V if it finds that the substance has: A low potential for abuse relative to the substances listed in Schedule IV, currently accepted medical use in treatment in the United States, and limited physical dependence and/or psychological dependence liability relative to the substances listed in Schedule IV.

Subd. 8.

Add, delete, or reschedule substances.

The state Board of Pharmacy may, by rule, add substances to or delete or reschedule substances listed in this section. The Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as provided in subdivision 12.

In making a determination regarding a substance, the Board of Pharmacy shall consider the following: The actual or relative potential for abuse, the scientific evidence of its pharmacological effect, if known, the state of current scientific knowledge regarding the substance, the history and current pattern of abuse, the scope, duration, and significance of abuse, the risk to public health, the potential of the substance to produce psychic or physiological dependence liability, and whether the substance is an immediate precursor of a substance already controlled under this section. The state Board of Pharmacy may include any nonnarcotic drug authorized by federal law for medicinal use in a schedule only if such drug must, under either federal or state law or rule, be sold only on prescription.

deleted text begin Subd. 8a. deleted text end

deleted text begin Methamphetamine precursors. deleted text end

deleted text begin The State Board of Pharmacy may, by order, require that nonprescription ephedrine or pseudophedrine products sold in gel capsule or liquid form be subject to the sale restrictions established in subdivision 6 for methamphetamine precursor drugs, if the board concludes that ephedrine or pseudophedrine products in gel capsule or liquid form can be used to manufacture methamphetamine. In assessing the need for an order under this subdivision, the board shall consult at least annually with the advisory council on controlled substances, the commissioner of public safety, and the commissioner of health. deleted text end

new text begin Subd. 8b. new text end

new text begin Board of Pharmacy; expedited scheduling of additional substances. new text end

new text begin (a) The state Board of Pharmacy may, by rule, add a substance to Schedule I provided that it finds that the substance has a high potential for abuse, has no currently accepted medical use in the United States, has a lack of accepted safety for use under medical supervision, has known adverse health effects, and is currently available for use within the state. For the purposes of this subdivision only, the board may use the expedited rulemaking process under section 14.389. The scheduling of a substance under this subdivision expires the day after the adjournment of the legislative session immediately following the substance's scheduling unless the legislature by law ratifies the action. new text end

new text begin (b) If the board schedules a substance under this subdivision, the board shall notify in a timely manner the chairs and ranking minority members of the senate and house of representatives committees having jurisdiction over criminal justice and health policy and finance of the action and the reasons for it. The notice must include a copy of the administrative law judge's decision on the matter. new text end

new text begin (c) This subdivision expires August 1, 2014. new text end

Subd. 9.

Except substances by rule.

The state Board of Pharmacy may by rule except any compound, mixture, or preparation containing any stimulant or depressant substance listed in subdivision 4, deleted text begin clauses (1) and (2)deleted text end new text begin paragraphs (b) and (c),new text end or in subdivisions 5 and 6 from the application of all or any part of this chapter, if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system; provided, that such admixtures shall be included therein in such combinations, quantity, proportion, or concentration as to vitiate the potential for abuse of the substances which do have a stimulant or depressant effect on the central nervous system.

Subd. 10.

Dextromethorphan.

Dextromethorphan shall not be deemed to be included in any schedule by reason of the enactment of Laws 1971, chapter 937, unless controlled pursuant to the foregoing provisions of this section.

Subd. 12.

Coordination of controlled substance regulation with federal law and state statute.

If any substance is designated, rescheduled, or deleted as a controlled substance under federal law and notice thereof is given to the state Board of Pharmacy, the state Board of Pharmacy shall similarly control the substance under this chapter, after the expiration of 30 days from publication in the Federal Register of a final order designating a substance as a controlled substance or rescheduling or deleting a substance. Such order shall be filed with the secretary of state. If within that 30-day period, the state Board of Pharmacy objects to inclusion, rescheduling, or deletion, it shall publish the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the state Board of Pharmacy shall publish its decision, which shall be subject to the provisions of chapter 14.

In exercising the authority granted by this chapter, the state Board of Pharmacy shall be subject to the provisions of chapter 14. deleted text begin The state Board of Pharmacy shall provide copies of any proposed rule under this chapter to the advisory council on controlled substances at least 30 days prior to any hearing required by section 14.14, subdivision 1. The state Board of Pharmacy shall consider the recommendations of the advisory council on controlled substances, which may be made prior to or at the hearing.deleted text end

The state Board of Pharmacy shall annually submit a report to the legislature on or before December 1 that specifies what changes the board made to the controlled substance schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in the preceding 12 months. The report must include specific recommendations for amending the controlled substance schedules contained in subdivisions 2 to 6, so that they conform with the controlled substance schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250.

deleted text begin Subd. 13. deleted text end

deleted text begin Implementation study. deleted text end

deleted text begin Annually, the state Board of Pharmacy shall study the implementation of this chapter in relation to the problems of drug abuse in Minnesota. deleted text end

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective August 1, 2012, and applies to crimes committed on or after that date. new text end

Sec. 2.

Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6, is amended to read:

Subd. 6.

Sale or possession of synthetic cannabinoids.

(a) As used in this subdivision, "synthetic cannabinoid" includes any substance included in section 152.02, subdivision 2, new text begin paragraph (h), new text end clause deleted text begin (7)deleted text end new text begin (3)new text end .

(b) new text begin A person who unlawfully sells a synthetic cannabinoid for no remuneration is guilty of a gross misdemeanor.new text end

new text begin (c) new text end A person who unlawfully sells deleted text begin any amount ofdeleted text end a synthetic cannabinoid is guilty of a deleted text begin gross misdemeanordeleted text end new text begin felony and if convicted may be sentenced to imprisonment for not more than five years or to payment of a fine of not more than $10,000, or bothnew text end .

deleted text begin (c)deleted text end new text begin (d)new text end A person who unlawfully possesses any amount of a synthetic cannabinoid is guilty of a misdemeanor.

deleted text begin (d)deleted text end new text begin (e)new text end Notwithstanding any contrary provision in sections 152.021 to 152.025, this subdivision describes the exclusive penalties for the sale and possession of synthetic cannabinoid.

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective August 1, 2012, and applies to crimes committed on or after that date. new text end

Sec. 3.

Minnesota Statutes 2010, section 152.18, subdivision 1, is amended to read:

Subdivision 1.

Deferring prosecution for certain first time drug offenders.

If any person who has not previously participated in or completed a diversion program authorized under section 401.065 or who has not previously been placed on probation without a judgment of guilty and thereafter been discharged from probation under this section is found guilty of a violation of section 152.024, subdivision 2, 152.025, subdivision 2, or 152.027, subdivision 2, 3, deleted text begin ordeleted text end 4,new text begin or 6, paragraph (d),new text end for possession of a controlled substance, after trial or upon a plea of guilty, and the court determines that the violation does not qualify as a subsequent controlled substance conviction under section 152.01, subdivision 16a, the court may, without entering a judgment of guilty and with the consent of the person, defer further proceedings and place the person on probation upon such reasonable conditions as it may require and for a period, not to exceed the maximum sentence provided for the violation. The court may give the person the opportunity to attend and participate in an appropriate program of education regarding the nature and effects of alcohol and drug abuse as a stipulation of probation. Upon violation of a condition of the probation, the court may enter an adjudication of guilt and proceed as otherwise provided. The court may, in its discretion, dismiss the proceedings against the person and discharge the person from probation before the expiration of the maximum period prescribed for the person's probation. If during the period of probation the person does not violate any of the conditions of the probation, then upon expiration of the period the court shall discharge the person and dismiss the proceedings against that person. Discharge and dismissal under this subdivision shall be without court adjudication of guilt, but a not public record of it shall be retained by the Bureau of Criminal Apprehension for the purpose of use by the courts in determining the merits of subsequent proceedings against the person. The not public record may also be opened only upon court order for purposes of a criminal investigation, prosecution, or sentencing. Upon request by law enforcement, prosecution, or corrections authorities, the bureau shall notify the requesting party of the existence of the not public record and the right to seek a court order to open it pursuant to this section. The court shall forward a record of any discharge and dismissal under this subdivision to the bureau which shall make and maintain the not public record of it as provided under this subdivision. The discharge or dismissal shall not be deemed a conviction for purposes of disqualifications or disabilities imposed by law upon conviction of a crime or for any other purpose.

For purposes of this subdivision, "not public" has the meaning given in section 13.02, subdivision 8a.

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective August 1, 2012, and applies to crimes committed on or after that date. new text end

Presented to the governor April 24, 2012

Signed by the governor April 27, 2012, 2:16 p.m.

Official Publication of the State of Minnesota
Revisor of Statutes